



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MANTHORPE *et al.*

Appl. No. 09/839,574

Filed: April 23, 2001

For: **Compositions and Methods for *in vivo* Delivery of Polynucleotide-Based Therapeutics**

Confirmation No.: 1437

Art Unit: 1635

Examiner: Schnizer, R.A.

Atty. Docket: 1530.0180002/EKS/EJH

#12/K.T.
1/7/03
B
RECEIVED

DEC 27 2002

Amendment And Reply Under 37 C.F.R. § 1.111

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Office Action dated June 24, 2002, (PTO Prosecution File Wrapper Paper No. 9), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.121 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R.